Literature DB >> 29090489

Reconstitution of T and NK cells after haploidentical hematopoietic cell transplantation using αβ T cell-depleted grafts and the clinical implication of γδ T cells.

Meerim Park1, Ho Joon Im2, Yu-Jin Lee3, Nuree Park3, Seongsoo Jang3,4, Seog Woon Kwon4, Chan-Jeoung Park4, Eun Seok Choi2, Kyung Nam Koh2, Jong Jin Seo2.   

Abstract

To investigate reconstitution of T and NK cells after αβ T lymphocyte-depleted haploidentical hematopoietic cell transplantation (HHCT) and the clinical implications of γδ T cells, we analyzed 50 pediatric patients who received 55 HHCTs using αβ T cell-depleted grafts. The number of CD3+ T cells and CD8+ T cells recovered rapidly and reached donor levels at days 180 and 60, respectively. Recovery of NK cells was rapid, and the median of NK cells at day 14 was comparable to the donor level. At day 14, median percentage of γδ T lymphocytes was 70.5%. After day 14, the percentage of γδ T cells gradually decreased, while the percentage of αβ T cells gradually increased. Patients with a low percentage (≤21%) of γδ T cells at day 30 had significantly higher incidence of cytomegalovirus (CMV) reactivation compared to patients with a high percentage (>70%) of γδ T cells (P < .01). In patients with acute leukemia, patients with high percentage of γδ T cells at day 30 showed significantly higher relapse-free survival compared to those with low percentage of γδ T cells (P = .02). Data suggest that early recovery of γδ T cells decreases the risk of CMV reactivation and leukemia relapse.
© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  haploidentical hematopoietic cell transplantation; reconstitution; γδ T cell

Mesh:

Substances:

Year:  2017        PMID: 29090489     DOI: 10.1111/ctr.13147

Source DB:  PubMed          Journal:  Clin Transplant        ISSN: 0902-0063            Impact factor:   2.863


  7 in total

1.  Impact of γδ T cells on clinical outcome of hematopoietic stem cell transplantation: systematic review and meta-analysis.

Authors:  Lucas C M Arruda; Ahmed Gaballa; Michael Uhlin
Journal:  Blood Adv       Date:  2019-11-12

Review 2.  An Unconventional View of T Cell Reconstitution After Allogeneic Hematopoietic Cell Transplantation.

Authors:  Hana Andrlová; Marcel R M van den Brink; Kate A Markey
Journal:  Front Oncol       Date:  2021-02-18       Impact factor: 6.244

3.  Haploidentical Stem Cell Transplantation in Children With Hematological Malignancies Using αβ+ T-Cell Receptor and CD19+ Cell Depleted Grafts: High CD56dim/CD56bright NK Cell Ratio Early Following Transplantation Is Associated With Lower Relapse Incidence and Better Outcome.

Authors:  Miguel A Diaz; Josune Zubicaray; Blanca Molina; Lorea Abad; Ana Castillo; Elena Sebastian; Eva Galvez; Julia Ruiz; Jose Luis Vicario; Manuel Ramirez; Julian Sevilla; Marta González-Vicent
Journal:  Front Immunol       Date:  2019-10-30       Impact factor: 7.561

Review 4.  Innate Immune Responses in the Outcome of Haploidentical Hematopoietic Stem Cell Transplantation to Cure Hematologic Malignancies.

Authors:  Elisa Zaghi; Michela Calvi; Clara Di Vito; Domenico Mavilio
Journal:  Front Immunol       Date:  2019-11-28       Impact factor: 7.561

5.  Immune reconstitution after T-cell replete HLA haploidentical hematopoietic stem cell transplantation using high-dose post-transplant cyclophosphamide.

Authors:  Yoshinobu Maeda
Journal:  J Clin Exp Hematop       Date:  2021-02-06

Review 6.  CMV Infection and CMV-Specific Immune Reconstitution Following Haploidentical Stem Cell Transplantation: An Update.

Authors:  Xiao-Hua Luo; Yan Zhu; Yu-Ting Chen; Li-Ping Shui; Lin Liu
Journal:  Front Immunol       Date:  2021-10-28       Impact factor: 7.561

Review 7.  Gamma delta T-cell reconstitution after allogeneic HCT: A platform for cell therapy.

Authors:  Ahmed Gaballa; Lucas C M Arruda; Michael Uhlin
Journal:  Front Immunol       Date:  2022-08-29       Impact factor: 8.786

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.